ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events

ME Staff 8-k
-
0

ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events
Item 8.01 Other Events

On June5, 2018, ContraVir Pharmaceuticals,Inc. issued a press release providing an informational update to stockholders regarding its rights offering and the key dates and terms relative to the offering.

The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

99.1

ContraVir Pharmaceuticals,Inc. Press Release dated June5, 2018


ContraVir Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a18-14945_1ex99d1.htm EX-99.1 Exhibit 99.1   ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering   EDISON,…
To view the full exhibit click here

About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.